Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

JAK-mutant myeloproliferative neoplasms.

Levine RL.

Curr Top Microbiol Immunol. 2012;355:119-33. doi: 10.1007/82_2011_170. Review.

PMID:
21823028
2.

Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.

Pasquier F, Cabagnols X, Secardin L, Plo I, Vainchenker W.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S23-35. doi: 10.1016/j.clml.2014.06.014. Review.

PMID:
25486952
3.

Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?

Pardanani A, Tefferi A.

Leuk Lymphoma. 2014 Dec;55(12):2706-11. doi: 10.3109/10428194.2014.985159. Review.

PMID:
25520049
4.

New JAK2 inhibitors for myeloproliferative neoplasms.

Quintás-Cardama A, Verstovsek S.

Expert Opin Investig Drugs. 2011 Jul;20(7):961-72. doi: 10.1517/13543784.2011.579560. Epub 2011 Apr 27. Review.

PMID:
21521147
5.

JAK and MPL mutations in myeloid malignancies.

Tefferi A.

Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360. Review.

PMID:
18297515
6.

Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.

Rosenthal A, Mesa RA.

Expert Opin Pharmacother. 2014 Jun;15(9):1265-76. doi: 10.1517/14656566.2014.913024. Epub 2014 Apr 25. Review.

PMID:
24766055
7.

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.

Bhagwat N, Levine RL, Koppikar P.

Int J Hematol. 2013 Jun;97(6):695-702. doi: 10.1007/s12185-013-1353-5. Epub 2013 May 14. Review.

PMID:
23670175
8.

JAK2 inhibitors: are they the solution?

Santos FP, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S28-36. doi: 10.1016/j.clml.2011.02.007. Epub 2011 May 4. Review.

9.

JAK2 mutations and clinical practice in myeloproliferative neoplasms.

Tefferi A.

Cancer J. 2007 Nov-Dec;13(6):366-71. Review.

PMID:
18032973
10.

Aspects biologiques de la voie JAK/STAT dans les néoplasmes myéloprolifératifs classiques négatifs pour BCR-ABL.

Mosca M, Vertenoeil G, Toppaldoddi KR, Plo I, Vainchenker W.

Bull Cancer. 2016 Jun;103(6 Suppl 1):S16-28. doi: 10.1016/S0007-4551(16)30142-4. Review. French.

PMID:
27494969
11.

JAK-2 mutations and their relevance to myeloproliferative disease.

Levine RL, Gilliland DG.

Curr Opin Hematol. 2007 Jan;14(1):43-7. Review.

PMID:
17133099
12.

Myeloproliferative disorders.

Levine RL, Gilliland DG.

Blood. 2008 Sep 15;112(6):2190-8. doi: 10.1182/blood-2008-03-077966. Review.

13.

Guidelines for the management of myeloproliferative neoplasms.

Choi CW, Bang SM, Jang S, Jung CW, Kim HJ, Kim HY, Kim SJ, Kim YK, Park J, Won JH.

Korean J Intern Med. 2015 Nov;30(6):771-88. doi: 10.3904/kjim.2015.30.6.771. Epub 2015 Oct 30. Review.

14.
15.

JAK2 kinase inhibitors and myeloproliferative disorders.

Chen AT, Prchal JT.

Curr Opin Hematol. 2010 Mar;17(2):110-6. doi: 10.1097/MOH.0b013e3283366b91. Review.

PMID:
20087176
16.

Targeting myeloproliferative neoplasms with JAK inhibitors.

Pardanani A, Tefferi A.

Curr Opin Hematol. 2011 Mar;18(2):105-10. doi: 10.1097/MOH.0b013e3283439964. Review.

PMID:
21245760
17.

The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.

Quintás-Cardama A.

Leuk Res. 2013 Apr;37(4):465-72. doi: 10.1016/j.leukres.2012.12.006. Epub 2013 Jan 11. Review.

PMID:
23313046
18.

JAK2 inhibitors in the treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Geyer HL, Mesa RA.

Expert Opin Investig Drugs. 2012 Dec;21(12):1755-74. doi: 10.1517/13543784.2012.721352. Epub 2012 Sep 19. Review.

PMID:
22991927
19.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
20.

Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.

Stein BL, Crispino JD, Moliterno AR.

Curr Opin Oncol. 2011 Nov;23(6):609-16. doi: 10.1097/CCO.0b013e32834d1b22. Review.

PMID:
21993415

Supplemental Content

Support Center